Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Impact of Frontline Treatment Strategy on Quality of Life in the First Decade after a Diagnosis of Marginal Zone Lymphoma

Côme Bommier, Mazie Tsang, Brie N. Noble, Carrie Thompson, Christopher Strouse, Carla Casulo, Eric Mou, Melissa C. Larson, Brianna Gysbers, Allison C. Rosenthal, Andrew L. Feldman, Matthew J. Maurer, Kathleen Yost, Susan L. Slager, Brian K. Link, Thomas M. Habermann, Amylou Constance Dueck, James R. Cerhan

Blood (2023) 142 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2023-186862

Published: 2023

Journal Articles

Longitudinal Analysis of Patient Reported Quality of Life in Newly Diagnosed Chronic Lymphocytic Leukemia Stratified By Initial Management Strategy: A Multi-Institutional Prospective Cohort Study

Amber Koehler, Brie N. Noble, Timothy G. Call, Sameer A. Parikh, Tait D. Shanafelt, Mazie Tsang, Côme Bommier, Kari G. Rabe, Christopher Strouse, Carrie Thompson, Paul J. Hampel, Kathleen Yost, Melissa C. Larson, Susan L. Slager, Brian K. Link, James R. Cerhan, Amylou Constance Dueck

Blood (2023) 142 (Supplement 1): 498.

https://doi.org/10.1182/blood-2023-187268

Published: 2023

Journal Articles

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Blood (2023) 142 (Supplement 1): 2395.

https://doi.org/10.1182/blood-2023-187056

Published: 2023

Journal Articles

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Blood (2023) 142 (Supplement 1): 3761.

https://doi.org/10.1182/blood-2023-188382

Published: 2023

Journal Articles

Duration Matters: Impact of Time from Diagnosis on Symptoms in Patients with Hematologic Malignancies

Leslie Padrnos, MD, Heidi Kosiorek, MS, Robert M Bennett, III, Amylou Constance Dueck, PhD, Krisstina L. Gowin, DO, Robyn M. Scherber, MD, Holly L. Geyer, MD, Jeanne Palmer, MD, Donald Northfelt, MD, Joseph R Mikhael, MD FRCPC, MD, Nandita Khera, MD, Ruben A Mesa, MD

Blood (2017) 130 (Supplement 1): 2162.

https://doi.org/10.1182/blood.V130.Suppl_1.2162.2162

Published: 2017

Journal Articles

Advanced Forms of the Myeloproliferative Neoplasms Are Associated with Chromosomal Abnormalities Involving 1q and 12q: Implicating MDM2 and MDM4 in Disease Progression

Bridget Marcellino, MD PhD, Joseph Tripodi, Min Lu, PhDMD, Heidi Kosiorek, MS, John Mascarenhas, MD, Raajit K. Rampal, MD PhD, Amylou Constance Dueck, PhD, Ronald Hoffman, MD, Vesna Najfeld, PhD

Blood (2017) 130 (Supplement 1): 204.

https://doi.org/10.1182/blood.V130.Suppl_1.204.204

Published: 2017

Journal Articles

Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study of 40,011 Patients

Natalie Ertz-Archambault, MD, Gretchen Taylor, MD, Heidi E. Kosiorek, MS, Amylou Constance Dueck, PhD, Janna Castro, Rob Marino, Susanne Gauthier, R.N., Katalin Kelemen, MD PhD, Laura E. Finn, MD, Lisa Sproat, MD MSW, Jeanne Palmer, MD, Ruben Mesa, MD FACP, Aref Al-Kali, MD, James M. Foran, MD, Raoul Tibes, MD PhD

Blood (2016) 128 (22): 296.

https://doi.org/10.1182/blood.V128.22.296.296

Published: 2016

Journal Articles

Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group

Robyn M. Scherber, MD MPH, Holly Geyer, MD, Amylou Constance Dueck, PhD, Heidi E. Kosiorek, MS, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Sonja Zweegman, MD PhD, Peter Te Boekhorst, Suzan Commandeur, MSc, Harry C. Schouten, Federico Sackmann, MD, Ana Kerguelen Fuentes, MD, Dolores Hernandez-Maraver, PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Konstanze Doehner, MD, Thomas Lehmann, Karen Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean Christophe Ianotto, Dana Ranta, MD, Lydia Roy, MD, Jean-Yves Cahn, MD, Claire N. Harrison, DM, FRCP, FRCPath, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Pablo J. Muxi, MD, Norman I Maldonado, MD, Carlos Besses, MD PhD, Francisco Cervantes, MD PhD, Peter L. Johansson, MD PhD, Tiziano Barbui, MD, Giovanni Barosi, Alessandro M. Vannucchi, MD, Bjorn Andreasson, Maria Ferarri, Alessandro Rambaldi, MD, Jan Samuelsson, MD PhD, Gunnar Birgegard, MD PhD, Keith Cannon, MD, Xuijuan Sun, Junqing Xu, Peihong Zhang, Zefeng Xu, Ruben A. Mesa, MD

Blood (2016) 128 (22): 3117.

https://doi.org/10.1182/blood.V128.22.3117.3117

Published: 2016

Journal Articles

Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

Blood (2016) 128 (22): 1929.

https://doi.org/10.1182/blood.V128.22.1929.1929

Published: 2016

Journal Articles

Differences in Cancer Education Between Patients with Hematologic Malignancies and Solid Tumor Malignancies: Lessons from a Large Multi-Disease Patient Education Symposium

Leslie Padrnos, MD, Robert Bennett, Heidi E. Kosiorek, MS, Joseph Mikhael, MD, Amylou Constance Dueck, PhD, Donald W. Northfelt, MD, Raoul Tibes, MD PhD, Nandita Khera, MD, Ruben A. Mesa, MD

Blood (2016) 128 (22): 4798.

https://doi.org/10.1182/blood.V128.22.4798.4798

Published: 2016

Journal Articles

Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

Tania Jain, M.B.,B.S, Shu Ting Kung, MD, Vishal Shah, Pharm.D., R.Ph., Amylou Constance Dueck, PhD, Heidi E. Kosiorek, MS, Joseph Mikhael, MD, P. Leif Bergsagel, MD, Craig B. Reeder, MD, Pierre Noel, MD, Roberta H. Adams, MD, Susan Luft, M.S., R.N., Angela Mayo, P.A.-C., M.S., A. Keith Stewart, M.B., Ch.B., Rafael Fonseca, MD

Blood (2016) 128 (22): 4629.

https://doi.org/10.1182/blood.V128.22.4629.4629

Published: 2016

Journal Articles

An Inhibitor of TGF-β Promotes Proliferation of Normal but Not MPN Hematopoietic Cells and Is a Candidate Therapeutic Agent for the Treatment of MPN Patients Carrying JAK2 V617F or Calr pQ365fs Mutations

Anna Rita Migliaccio, PhD, Camelia Iancu-Rubin, PhD, Rona Singer Weinberg, PhD, Ronald Hoffman, MD, Amylou Constance Dueck, PhD, John O. Mascarenhas, MD MS

Blood (2015) 126 (23): 4089.

https://doi.org/10.1182/blood.V126.23.4089.4089

Published: 2015

Journal Articles

Living with Cancer: An Educational Intervention in Cancer Patients Can Improve Knowledge Deficit

Leslie Padrnos, MD, Joseph Mikhael, MD, Robert Bennett, Heidi Kosiorek, Amylou Constance Dueck, PhD, Donald W. Northfelt, MD, Raoul Tibes, MD PhD, Nandita Khera, MD, Ruben A. Mesa, MD

Blood (2015) 126 (23): 3321.

https://doi.org/10.1182/blood.V126.23.3321.3321

Published: 2015

Journal Articles

Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis

Krisstina L. Gowin, DO, Heidi E. Kosiorek, MS, Amylou Constance Dueck, PhD, John Mascarenhas, Ronald Hoffman, MD, Craig B. Reeder, MD, John Camoriano, MD, Veena Fauble, MD, Raoul Tibes, MD, Katherine Gano, MS, Vineta Ghurye, Patricia Koenig, Ruben A. Mesa

Blood (2015) 126 (23): 1618.

https://doi.org/10.1182/blood.V126.23.1618.1618

Published: 2015

Journal Articles

Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study

Natalie Ertz-Archambault, MD, Heidi Kosiorek, M.S., Janna Castro, Gretchen Taylor, MD, Robert Marino, Amylou Constance Dueck, PhD, Aref Al-Kali, MD, Susanne Gauthier, R.N., Laura E. Finn, MD, James M. Foran, MD, Lisa Sproat, MD MSW, Raoul Tibes, MD PhD

Blood (2015) 126 (23): 5636.

https://doi.org/10.1182/blood.V126.23.5636.5636

Published: 2015

Journal Articles

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory (IMiD) Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma

Brenda Ernst, MD, Amylou Constance Dueck, PhD, Angela Toro, NP, Patrick B. Johnston, MD PhD, Thomas Haberman, MD, Jose F. Leis, MD PhD, Joseph R. Mikhael, MD, Grzegorz S. Nowakowski, MD, Joseph P. Colgan, MD, Luis F. Porrata, MD, James L Slack, MD, Stephen M. Ansell, MD PhD, Thomas E. Witzig, MD, Craig B. Reeder, MD

Blood (2014) 124 (21): 3100.

https://doi.org/10.1182/blood.V124.21.3100.3100

Published: 2014

Journal Articles

The Clinical Phenotype of Patients with Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis Whom Only Manifest WHO Grade 1 Fibrosis

Krisstina L. Gowin, DO, Amylou Constance Dueck, PhD, Srdan Verstovsek, MD PhD, Naval Daver, MD, Naveen Pemmaraju, MD, Riccardo Valdez, MD, Ruben A. Mesa, MD

Blood (2014) 124 (21): 3208.

https://doi.org/10.1182/blood.V124.21.3208.3208

Published: 2014

Journal Articles

High Prevalence of Mood Disorders in MPNs and Their Possible Role in MPN Related Fatigue

Robyn M Scherber, MD MPH, Zhenya Senyak, Amylou Constance Dueck, PhD, Matthew Clark, PhD LP, Michael Boxer, MD, Archie McCallister, MD, Mary Cotter, Barbara VanHusen, Claire N Harrison, DM, FRCP, FRCPath, Ruben Mesa, MD

Blood (2014) 124 (21): 3173.

https://doi.org/10.1182/blood.V124.21.3173.3173

Published: 2014

Journal Articles

A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma

Allison C. Rosenthal, DO, Amylou Constance Dueck, PhD, Katherine Gano, MS, Craig Nichols, Daniel Johnson, Angela Toro, NP, Sravan Nagi Reddy, James L Slack, MD, Jose F Leis, MD PhD, Donald W. Northfelt, MD, P. Leif Bergsagel, MD, Rodger Tiedemann, MBChB, PhD, Patrick B. Johnston, MD PhD, Thomas M Habermann, MD, Thomas E. Witzig, MD, Craig B. Reeder, MD

Blood (2014) 124 (21): 4410.

https://doi.org/10.1182/blood.V124.21.4410.4410

Published: 2014

Journal Articles

Understanding and Information in Cancer Patients: The Impact of a Cancer Symposia on Patient Knowledge

Leslie J Padrnos, MD, Qing Wu, Sc.D., Robyn M Scherber, MPH, Donald W. Northfelt, MD, Joseph R. Mikhael, MD, Robert M. Bennett, Amylou Constance Dueck, PhD, Ruben Mesa, MD

Blood (2014) 124 (21): 6011.

https://doi.org/10.1182/blood.V124.21.6011.6011

Published: 2014

NARROW

Impact of Frontline Treatment Strategy on Quality of Life in the First Decade after a Diagnosis of Marginal Zone Lymphoma

Longitudinal Analysis of Patient Reported Quality of Life in Newly Diagnosed Chronic Lymphocytic Leukemia Stratified By Initial Management Strategy: A Multi-Institutional Prospective Cohort Study

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Duration Matters: Impact of Time from Diagnosis on Symptoms in Patients with Hematologic Malignancies

Advanced Forms of the Myeloproliferative Neoplasms Are Associated with Chromosomal Abnormalities Involving 1q and 12q: Implicating MDM2 and MDM4 in Disease Progression

Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study of 40,011 Patients

Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group

Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

Differences in Cancer Education Between Patients with Hematologic Malignancies and Solid Tumor Malignancies: Lessons from a Large Multi-Disease Patient Education Symposium

Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

An Inhibitor of TGF-β Promotes Proliferation of Normal but Not MPN Hematopoietic Cells and Is a Candidate Therapeutic Agent for the Treatment of MPN Patients Carrying JAK2 V617F or Calr pQ365fs Mutations

Living with Cancer: An Educational Intervention in Cancer Patients Can Improve Knowledge Deficit

Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis

Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory (IMiD) Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma

The Clinical Phenotype of Patients with Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis Whom Only Manifest WHO Grade 1 Fibrosis

High Prevalence of Mood Disorders in MPNs and Their Possible Role in MPN Related Fatigue

A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma

Understanding and Information in Cancer Patients: The Impact of a Cancer Symposia on Patient Knowledge

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only